Inicio › Trastorno depresivo mayor › Arkansas
Ensayos clínicos de Trastorno depresivo mayor en Arkansas
13 estudios sobre Trastorno depresivo mayor buscan participantes en Arkansas.
Ciudades en Arkansas
Texto oficial del estudio (inglés)
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Preferred Research Partners, Inc., Little Rock
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 9 nov 2026 · NCT07592689Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 nov 2026 · NCT06559306A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 nov 2026 · NCT07573176Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
- Neurocrine Clinical Site, Little Rock
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 nov 2026 · NCT06966401Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Woodland Research Northwest (ERG), Rogers
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 28 oct 2026 · NCT07226661Study of ALTO-300 in MDD
- Site 193, Rogers
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 26 oct 2026 · NCT05922878A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Little Rock
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 14 oct 2026 · NCT07610473A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
- Draig Clinical Site, Bentonville
- Draig Clinical Site, Little Rock
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 8 oct 2026 · NCT07300969Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Little Rock
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Bryant
ReclutandoFase 4
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT07105111NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Bryant
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT06911112A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Preferred Research Partners /ID# 279206, Little Rock
- Woodland International Research Group /ID# 277605, Little Rock
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 15 jun 2026 · NCT07276997Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Little Rock
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2025 · NCT06786624De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.